









Markets
/
Stocks
/
nasdaq-howl
/

Werewolf Therapeutics Inc

HOWL

1.490USD

+0.040+2.76%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

67.55MMarket Cap

LossP/E TTM



Werewolf Therapeutics Inc

1.490

+0.040+2.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

118 / 506

Overall Ranking

221 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

6.833

Target Price

+371.26%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.89M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 31.04.

Undervalued

The company’s latest PE is -0.91, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.29M shares, decreasing 17.23% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.30M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.73.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 4.25%.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.88, which is -26.90% below the recent high of -0.64 and 9.65% above the recent low of -0.80.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.33, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Werewolf Therapeutics Inc is 7.00, with a high of 10.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

9.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

6.833

Target Price

+371.26%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Werewolf Therapeutics Inc

HOWL

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.04, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.57 and the support level at 1.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.04

Change

-0.3

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.015

Buy

RSI(14)

64.483

Neutral

STOCH(KDJ)(9,3,3)

78.839

Buy

ATR(14)

0.072

High Vlolatility

CCI(14)

108.150

Buy

Williams %R

9.091

Overbought

TRIX(12,20)

0.479

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.444

Buy

MA10

1.419

Buy

MA20

1.382

Buy

MA50

1.324

Buy

MA100

1.223

Buy

MA200

1.256

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 67.51%, representing a quarter-over-quarter decrease of 0.75%. The largest institutional shareholder is The Vanguard, holding a total of 1.30M shares, representing 2.84% of shares outstanding, with 10.97% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

6.68M

+8.73%

MPM Capital Inc.

4.31M

MPM BioImpact LLC

2.41M

+0.87%

BofA Global Research (US)

2.10M

+1.17%

Arkin Bio Ventures LP

2.05M

The Vanguard Group, Inc.

Star Investors

1.51M

+6.23%

Millennium Management LLC

784.62K

+31.58%

Hicklin Daniel J

647.05K

Sphera Funds Management Ltd.

626.81K

DC Funds, LP

589.10K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.